| Literature DB >> 29165122 |
Geon-Woo Lee1,2, Mun-Joo Bae3, Ji-Yeon Yang2, Jung-Woo Son4, Jae-Lim Cho5, Sang-Gyu Lee2, Bo-Mi Jang2, Hyun-Woo Lee6, Jong-Soon Lim6, Dong-Chun Shin2,4, Young-Wook Lim7.
Abstract
BACKGROUND: Carbon monoxide (CO) is one of the primary components of emissions from light-duty vehicles, and reportedly comprises 77% of all pollutants emitted in terms of concentration. Exposure to CO aggravates cardiovascular disease and causes other health disorders. The study was aimed to assess the negative effects by injecting different amounts of CO concentration directly to human volunteers boarding in the car.Entities:
Keywords: Blood pressure; Carbon monoxide; Carboxyhemoglobin; Fatigue; In-vehicle
Mesh:
Substances:
Year: 2017 PMID: 29165122 PMCID: PMC5664420 DOI: 10.1186/s12199-017-0622-y
Source DB: PubMed Journal: Environ Health Prev Med ISSN: 1342-078X Impact factor: 3.674
Comparison of carbon monoxide levels in a vehicle cabin, as measured by other studies
| Study location | CO level, ppm (range) | Type of vehicle | Source |
|---|---|---|---|
| Paris, France | 3.8 | Taxi | [ |
| Guangzhou, China | 28.7 (10.5-46.1) | Taxi (A/C) | [ |
| Athens, Greece | 21.4 (14.6-40.0) | Private car | [ |
| London, UK | 1.3 (0–2.5) | Private car | [ |
| Beirut, Lebanon | 20.0 (0–120.5) | Private car | [ |
| Hanoi, Vietnam | 18.5 | Private car | [ |
| Beirut, Lebanon | 30.8 (20.4-43.2) | Private car | [ |
| Jakarta, Indonesia | 22.0 | Private car | [ |
| Tel Aviv, Israel | 11.6 (5.9-27.2) | Private car | [ |
Fig. 1The test site and the car used for the carbon monoxide exposure test
The health status of participants, as confirmed through medical examinations prior to exposure to carbon monoxide
| Participants of first test | Participants of second test | |||||
|---|---|---|---|---|---|---|
| Men | Women | Total | Men | Women | Total | |
| Age (Year) | 42.2 ± 12.6 | 39.0 ± 12.9 | 40.8 ± 12.6 | 38.5 ± 13.3 | 40.4 ± 10.8 | 39.5 ± 11.8 |
| BMI (kg m-2) | 24.4 ± 3.6 | 22.5 ± 2.4 | 23.6 ± 3.2 | 24.1 ± 3.7 | 22.7 ± 2.9 | 23.4 ± 3.4 |
| Systolic blood pressure (mmHg) | 123.2 ± 13.6 | 118.7 ± 9.0 | 121.3 ± 11.8 | 125.3 ± 13.4 | 121.3 ± 13.3 | 123.3 ± 13.2 |
| Diastolic blood pressure (mmHg) | 76.8 ± 11.0 | 73.9 ± 7.6 | 75.6 ± 9.6 | 75.6 ± 9.8 | 70.8 ± 8.2 | 73.2 ± 9.2 |
| Red blood cell (109 cells/L) | 4.7 ± 0.4 | 4.3 ± 0.2 | 4.5 ± 0.3 | 5.0 ± 0.3 | 4.5 ± 0.2 | 4.8 ± 0.4 |
| White blood cell (109 cells/L) | 6.2 ± 1.1 | 6.5 ± 1.6 | 6.4 ± 1.3 | 6.1 ± 1.0 | 6.5 ± 1.8 | 6.3 ± 1.4 |
| Platelets (109 cells/L) | 242.6 ± 48.9 | 272.4 ± 47.4 | 255.6 ± 49.5 | 250.0 ± 60.1 | 282.2 ± 55.5 | 266.1 ± 58.7 |
| High sensitive C-reactive protein (mg/L) | 1.7 ± 3.4 | 0.6 ± 0.4 | 1.2 ± 2.6 | 0.7 ± 0.4 | 1.0 ± 0.8 | 0.9 ± 0.7 |
| Total cholesterol (mg/dL) | 178.5 ± 33.4 | 193.2 ± 38.7 | 184.9 ± 35.7 | 191.6 ± 33.4 | 203.9 ± 47.1 | 197.8 ± 40.3 |
| High density lipoprotein cholesterol (mg/dL) | 51.8 ± 10.3 | 59.8 ± 11.7 | 55.3 ± 11.4 | 58.1 ± 10.4 | 59.0 ± 8.6 | 58.6 ± 9.3 |
Results of carbon monoxide measurement during the first and second exposure tests
| Targeted concentration of CO (ppm) | Measured CO concentration, ppm (Mean ± S.D) |
| |
|---|---|---|---|
| First test | 0 | 0.0 ± 0.1 | <0.001 |
| 30 | 33.2 ± 1.9 | ||
| 70 | 72.4 ± 1.4 | ||
| Second test | 0 | 0.2 ± 0.3 | <0.001 |
| 30 | 30.2 ± 3.5 | ||
| 50 | 48.8 ± 3.7 |
Data were expressed as means with standard deviation. The one-way Analysis of Variance (ANOVA) was used to compare CO means measured in the first and second tests
Carboxyhemoglobin levels of participants after the first and second tests
| COHb levels in the first test ( | COHb levels in second test ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.2 ppm in comparison with 0 ppm | 72.4 ppm in comparison with 0 ppm | 30.2 ppm in comparison with 0 ppm | 48.8 ppm in comparison with 0 ppm | |||||||||
| 0 ppm | 33.2 ppm | Delta | 0 ppm | 72.4 ppm | Delta | 0 ppm | 30.2 ppm | Delta | 0 ppm | 48.8 ppm | Delta | |
| COHb (%) | 1.2 | 1.6 | 0.4*
| 1.2 | 2.4 | 1.2*
| 1.2 | 1.6 | 0.4*
| 1.2 | 2.3 | 1.0*
|
Data were expressed as medians with inter-quartile range. Wilcoxon’s Signed-Rank test was used for evaluation of differences between delta changes. P values of < 0.05 were considered significant. * P < 0.05
Blood pressure results of participants after the first and second tests
| Blood pressure after the first test ( | Blood pressure after the second test ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.2 ppm in comparison with 0 ppm | 72.4 ppm in comparison with 0 ppm | 30.2 ppm in comparison with 0 ppm | 48.8 ppm in comparison with 0 ppm | |||||||||
| 0 ppm | 33.2 ppm | Delta | 0 ppm | 72.4 ppm | Delta | 0 ppm | 30.2 ppm | Delta | 0 ppm | 48.8 ppm | Delta | |
| Systolic pressure (mmHg) | 137.0 | 133.0 | −2.0 | 137.0 | 132.0 | −5.0 | 121.5 | 116.5 | −5.0 | 121.5 | 120.5 | −3.0 |
| Diastolic pressure (mmHg) | 86.0 | 80.0 | −2.0 | 86.0 | 81.0 | −6.0*
| 74.5 | 70.0 | −3.0 | 74.5 | 71.0 | −5.0*
|
Data were expressed as medians with inter-quartile range. Wilcoxon’s Signed-Rank test was used for evaluation of differences between delta changes. P values of < 0.05 were considered significant. * P < 0.05
Fig. 2The results of a medical interview of participants after exposure depending on the concentration of carbon monoxide. Friedman test and Wilcoxon test as a post hoc analysis performed to analyze the difference among participants reporting symptoms after exposure to carbon monoxide. Data were considered significant at *P < 0.05
COHb levels of the participants who underwent the first and second tests
| Targeted concentration of CO (ppm) | First test, % (n) | Second test, % (n) | Total, % (n) |
|
|---|---|---|---|---|
| 0 | 1.3 (14) | 1.1 (14) | 1.2 (28) | <0.001 |
| 30 | 1.8 (14) | 1.5 (14) | 1.7 (28) | |
| 50 | - | 2.2 (14) | 2.2 (14) | |
| 70 | 2.5 (14) | - | 2.5 (14) |
Wilcoxon’s signed-rank test was used to analyze the COHb levels of the participants who underwent the first and second tests